Maija P. Valta

Maija P. Valta

Auto-generated profile, based on publicly available information

Maija P. Valta

Institute of Biomedicine, Department of Anatomy, University of Turku, Finland

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2006 in Endocrinology
Verified
Journal Article
Closed access
MVMaija P. Valta
Maija P. Valta
THTeuvo Hentunen
Teuvo Hentunen
QQQiang Qu
Qiang Qu
EVEeva M. Valve
Eeva M. Valve
AHAnna Harjula
Anna Harjula
PHPirkko L. Härkönen
Pirkko L. Härkönen
Several members of the fibroblast growth factor (FGF) family have an important role in the development of skeletal tissues. FGF-8 is widely expressed in the developing skeleton, but its function there has remained unknown. We asked in this study whether FGF-8 could have a role in the differentiation of mesenchymal stem cells to an osteoblastic lineage. Addition of FGF-8 to mouse bone marrow cultures effectively increased initial cell proliferation as well as subsequent osteoblast-specific alkaline phosphatase production, bone nodule formation, and calcium accumulation if it was added to the cultures at an early stage of osteoblastic differentiation. Exogenous FGF-8 also stimulated the proliferation of MG63 osteosarcoma cells, which was blocked by a neutralizing antibody to FGF-8b. In addition, the heparin-binding growth factor fraction of Shionogi 115 (S115) mouse breast cancer cells, which express and secrete FGF-8 at a very high level, had an effect in bone marrow cultures similar to that of exogenous FGF-8. Interestingly, experimental nude mouse tumors of S115 cells present ectopic bone and cartilage formation as demonstrated by typical histology and expression of markers specific for cartilage (type II and IX collagen) and bone (osteocalcin). These results demonstrate that FGF-8 effectively predetermines bone marrow cells to differentiate to osteoblasts and increases bone formation in vitro. It is possible that FGF-8 also stimulates bone formation in vivo. The results suggest that FGF-8, which is expressed by a great proportion of malignant breast and prostate tumors, may, among other factors, also be involved in the formation of osteosclerotic bone metastases.

24 April 2008 in International Journal of Cancer
Verified
Journal Article
Open access
PDF file
MVMaija P. Valta
Maija P. Valta
JTJohanna Tuomela
Johanna Tuomela
ABAnders Bjartell
Anders Bjartell
EVEeva Valve
Eeva Valve
HVH. Kalervo Väänänen
H. Kalervo Väänänen
PHPirkko Härkönen
Pirkko Härkönen
Prostate cancer is the most common malignancy of men in Western countries. Patients with advanced prostate cancer suffer from incurable bone metastases. Recent data indicate that interactions between prostate cancer cells, osteoblasts, osteoclasts and the bone matrix are essential in the formation of bone metastases. FGF‐8 is widely overexpressed in prostate cancer. Recently, FGF‐8 has been found to affect both osteoblast and osteoclast differentiation. The aim of this study was to examine the role of FGF‐8 in bone metastasis of prostate cancer. Immunohistochemistry was used to analyse FGF‐8 expression in clinical samples of prostate cancer bone metastases. The functional significance of FGF‐8 in growth of bone metastasis and formation of bone lesions was verified by using intratibial inoculations of FGF‐8 or mock transfected PC‐3 prostate cancer cells in nude mice. Intratibial tumors and bone lesions were analysed with X‐ray, micro‐CT and detailed histomorphometry using image analysis software and with immunostaining for osteocalcin and cathepsin K. Immunohistochemical analysis of tissue microarray of bone metastases of human prostate cancer showed that 76% of human bone metastasis samples (n = 25 from 11 patients) were positive for FGF‐8. FGF‐8 increased the growth of intratibial tumors and local formation of lytic and sclerotic lesions of bone. These results demonstrate that FGF‐8 is expressed at a high frequency in bone metastases of human prostate cancer and that expression of FGF‐8 in PC‐3 prostate cancer cells increases their growth as intratibial tumors and modulates formation of bone lesions in an in vivo model of prostate cancer bone metastasis.

25 March 2014 in Advanced Healthcare Materials
Verified
Journal Article
Closed access
PDF file
KPKanyi Pu
Kanyi Pu
ASAdam J. Shuhendler
Adam J. Shuhendler
MVMaija P. Valta
Maija P. Valta
LCLina Cui
Lina Cui
MSMatthias Saar
Matthias Saar
JRJianghong Rao
Jianghong Rao

1 January 2014 in Urologic Oncology: Seminars and Original Investigations
Verified
Journal Article
Closed access
ATAlan Thong
Alan Thong
HZHongjuan Zhao
Hongjuan Zhao
AIAlexandre Ingels
Alexandre Ingels
MVMaija P. Valta
Maija P. Valta
RNRosalie Nolley
Rosalie Nolley
DPDonna M. Peehl
Donna M. Peehl

31 October 2013 in International Journal of Cancer
Verified
Journal Article
Open access
PDF file
AIAlexandre Ingels
Alexandre Ingels
HZHongjuan Zhao
Hongjuan Zhao
ATAlan Thong
Alan Thong
MSMatthias Saar
Matthias Saar
MVMaija P. Valta
Maija P. Valta
DPDonna M. Peehl
Donna M. Peehl
MTOR is a rational target in renal cell carcinoma (RCC) because of its role in disease progression. However, the effects of temsirolimus, the only first‐generation mTOR inhibitor approved by the FDA for first‐line treatment of metastatic RCC, on tumor reduction and progression‐free survival are minimal. Second‐generation mTOR inhibitors have not been evaluated on RCC. We compared the effects of temsirolimus and MLN0128, a potent second‐generation mTOR inhibitor, on RCC growth and metastasis using a realistic patient‐derived tissue slice graft (TSG) model. TSGs were derived from three fresh primary RCC specimens by subrenal implantation of precision‐cut tissue slices into immunodeficient mice that were randomized and treated with MLN0128, temsirolimus, or placebo. MLN0128 consistently suppressed primary RCC growth, monitored by magnetic resonance imaging (MRI), in three TSG cohorts for up to 2 months. Temsirolimus, in contrast, only transiently inhibited the growth of TSGs in one of two cohorts before resistance developed. In addition, MLN0128 reduced liver metastases, determined by human‐specific quantitative polymerase chain reaction, in two TSG cohorts, whereas temsirolimus failed to have any significant impact. Moreover, MLN0128 decreased levels of key components of the two mTOR subpathways including TORC1 targets 4EBP1, p‐S6K1, HIF1α and MTA1 and the TORC2 target c‐Myc, consistent with dual inhibition. Our results demonstrated that MLN0128 is superior to temsirolimus in inhibiting primary RCC growth as well as metastases, lending strong support for further clinical development of dual mTOR inhibitors for RCC treatment.

28 March 2008 in BMC Cancer
Verified
Journal Article
Open access
PDF file
JTJohanna Tuomela
Johanna Tuomela
MVMaija P Valta
Maija P Valta
KVKalervo Väänänen
Kalervo Väänänen
PHPirkko Härkönen
Pirkko Härkönen
Metastatic prostate cancer is associated with a high morbidity and mortality but the spreading mechanisms are still poorly understood. The aminobisphosphonate alendronate, used to reduce bone loss, has also been shown to inhibit the invasion and migration of prostate cancer cells in vitro. We used a modified orthotopic PC-3 nude mouse tumor model of human prostate cancer to study whether alendronate affects prostate tumor growth and metastasis.